"Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine
Orally administered Salmonella enterica serovar Typhimurium colonizes the gut-associated lymphoid tissue (Peyer's patches) and the secondary lymphatic tissues, including the liver and spleen, to elicit anti-Salmonella immune responses during infection of the mouse. (17) . The immune responsiveness to orally administered Salmonella has been applied to develop live attenuated oral Salmonella vaccines (13) . Attenuated Salmonella vaccines have been constructed by introduction of mutations in the genes required for virulence, including the cyclic AMP receptor protein gene (crp) (12) . Crp is a global regulator involved in a variety of biological functions, including carbohydrate utilization (4) . Attenuated Salmonella vaccine strains have been genetically modified to express another pathogen's antigen (s) specified by multicopy plasmids. These recombinant vaccines induce immunity to the pathogen whose antigen gene is expressed as well as to Salmonella. It is essential that the antigen-specifying plasmids in Salmonella vaccines are stably maintained during the in vivo colonization process. A balanced-lethal host-vector system based on the essential bacterial gene for aspartate ␤-semialdehyde dehydrogenase (asd) has been used to specify recombinant antigens from Asd ϩ plasmids that are retained in vivo in Salmonella vaccine strains with the asd gene deleted (16, 36) .
Streptococcus pneumoniae is a human pathogen that causes life-threatening diseases, including community-acquired pneumonia, otitis media, meningitis, and bacteremia, in persons of all ages (35) . S. pneumoniae is the leading cause of childhood pneumonia worldwide, resulting in about 3 million deaths per year (21) . The recent emergence of antibiotic-resistant strains has the potential to threaten the treatment of pneumococcal disease in the near future (5) . Thus, the development of a safe, effective, and lower-cost antipneumococcal vaccine is urgently needed. Capsular polysaccharide-based pneumococcal vaccines are currently available and are moderately effective. A 23-valent pneumococcal polysaccharide vaccine is recommended for the prevention of infection in adults (48) , and a 7-valent conjugated polysaccharide vaccine is licensed for use in children (49) . However, vaccination with the pneumococcal polysaccharide vaccine does not reduce the frequency of hospitalization, costs, and mortality caused by pneumococcal pneumonia (23) , which reinforces the need for effective new vaccines.
Studies on the protective efficacy of subunit vaccines may further the development of a more protective pneumococcal vaccine. The pneumococcal PspA (pneumococcal surface protein A) protein has been evaluated and considered to be a pneumococcal vaccine candidate because of its immunogenicity and protection of mice against challenge with virulent S. pneumoniae (6, 8, 9, 25) . Native PspA Rx1 (PspA originating from S. pneumoniae strain Rx1) contains several functional domains: an N-terminal signal sequence, an ␣-helical region, a proline-rich domain, 10 tandem-repeat choline-binding regions, and a 17-amino-acid residue carboxy terminus. Pneumococcal protection assays with mice immunized with various recombinant PspA Rx1 oligopeptides showed that the ␣-helical domain contains the protective epitopes (7) . In a previous study, mice orally immunized with an S. enterica serovar Typhimurium vaccine strain expressing a recombinant PspA Rx1 (from the ATG start codon specifying the native signal sequence, the entire ␣-helical domain, and up to the fifth tandem repeat) showed PspA-specific immune responses and were protected against challenge with virulent S. pneumoniae (37) . Expression of recombinant PspA (rPspA) in this recombinant Salmonella vaccine strain was somewhat toxic, such that the high-copy-number plasmid pYA3193 (pUC ori) was relatively unstable. Thus, approximately 50% of cells lost the plasmid after 24 h of growth as a standing culture in the presence of diaminopimelic acid (DAP). This phenomenon forced us to construct an improved plasmid vector to enable stable expression of rPspA in attenuated Salmonella. An additional goal of our research is to construct recombinant attenuated Salmonella vaccines that induce higher immune responses to the foreign expressed antigen than to Salmonella antigens.
In this work, we constructed a stable multicopy Asd ϩ antigen expression vector encoding the ␤-lactamase signal sequence fused in frame to the immunogenic ␣-helical region of PspA. This plasmid was designed to translocate PspA into the periplasmic space of the Salmonella vaccine strain, although about 25% of the synthesized PspA reached the supernatant fluid without cell lysis. We report the immunogenicity, type of immune responses, and protection against both Salmonella and S. pneumoniae in mice immunized with a Salmonella vaccine expressing rPspA by an improved antigen expression system.
MATERIALS AND METHODS
Bacterial strains, plasmids, media, and growth conditions. The bacterial strains and plasmids used in this study are listed in Table 1 . Bacteriophage P22HTint (46) was used for generalized transduction. Escherichia coli and S. enterica serovar Typhimurium cultures were grown at 37°C in Lennox broth (29) or Luria-Bertani (LB) broth or on LB agar (1) . MacConkey agar (Difco, Detroit, Mich.) supplemented with 1% sugar was used for fermentation assays. When required, antibiotics were added to culture media at the following concentrations: ampicillin, 100 g/ml; chloramphenicol, 30 g/ml; kanamycin, 50 g/ml; and tetracycline, 15 g/ml. DAP was added (50 g/ml) for the growth of Asd Ϫ strains (36) . LB agar containing 5% sucrose was used for sacB gene-based (18) . S. pneumoniae WU2 was cultured on brain heart infusion agar containing 5% sheep blood or in ToddHewitt broth plus 0.5% yeast extract (6) . General DNA procedures. DNA manipulations were carried out as described by Sambrook et al. (45) . Transformation of E. coli and Salmonella was done by electroporation (Bio-Rad, Hercules, Calif.). Transformants containing Asd ϩ plasmids were selected on L agar plates without DAP. Only clones containing the recombinant plasmids were able to grow under these conditions. Transfer of recombinant suicide plasmids to Salmonella was accomplished by conjugation using E. coli MGN-617 (Asd Ϫ ) (44) as the plasmid donor. Bacteriophage P22HT int-mediated general transduction was performed by standard methods (52) . PCR amplification was employed to obtain DNA fragments for cloning and for verification of chromosomal deletion mutations. The PCR conditions were as follows: denaturation at 95°C for 20 s, primer annealing at 55°C for 20 s, polymerization at 72°C for 2 min, and a final extension at 72°C for 10 min. Nucleotide sequencing reactions were performed using ABI Prism fluorescent Big Dye terminators according to the instructions of the manufacturer (PE Biosystems, Norwalk, Conn.).
Characterization of phenotype. MacConkey agar supplemented with 1% maltose was used to detect the phenotypes of Salmonella crp mutants. Motility was evaluated by observing Salmonella spread on a semisolid medium composed of 1% casein enzyme hydrolysate, 0.5% NaCl, and 0.5% agar. Triphenyltetrazolium chloride (50 g/ml) was added to motility medium to observe Salmonella as red cells. The presence of the ⌬asdA16 mutation in Salmonella was confirmed by inability of the strain to grow on media without DAP (36) . Lipopolysaccharide (LPS) profiles of Salmonella strains were examined by previously described methods (24) .
SDS-PAGE and immunoblot analyses. Protein samples were boiled for 5 min and then separated by discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Protein bands were visualized by Coomassie brilliant blue R250 (Sigma, St. Louis, Mo.) staining. For immunoblotting, proteins separated by SDS-PAGE were transferred eletrophoretically to nitrocellulose membranes. The membranes were blocked with 3% bovine serum albumin in 10 mM Tris-0.9% NaCl (pH 7.4) and incubated with mouse monoclonal antibodies specific for PspA (Xi126) (32), OmpC (50), or ␤-galactosidase (Sigma) and then with a peroxidase-conjugated goat anti-mouse immunoglobulin G (IgG) (BioRad). Immunoreactive bands were detected by the addition of 4-chloro-1-naphthol (Sigma) in the presence of H 2 O 2 . The reaction was stopped after 2 min by washing with several large volumes of deionized water.
Purification of rPspA. For overexpression of His 6 -tagged PspA, a fragment of the pspA gene specifying the ␣-helical region from amino acid residue 3 to 257 of the mature PspA protein of S. pneumoniae Rx1 was PCR amplified from pYA3193 (37) template DNA using a pair of primers (N terminal, 5ЈCCGGAA TTCATCACCATCACCATCACTCTCCCGTAGCCAGTCAGT3Ј; C terminal, 5ЈGGGAAGCTTCTATTATTCTACATTATTGTT3Ј). The 0.8-kb amplified fragment was then cloned into the pYA3342 vector, resulting in pYA3496 ( Table  1 ). The N-terminal primer contains an EcoRI site (underlined) and six consecutive histidine codons (alternate use of CAT and CAC; boldface) for His 6 tagging at the N terminus. The C-terminal primer specifies two consecutive stop codons (TAA TAG; boldface) followed by a HindIII site (underlined). In-frame cloning was confirmed by nucleotide sequencing. E. coli 6212 harboring pYA3496 expressed a large amount of soluble His 6 -tagged rPspA in its cytoplasm. According to the protocol of the manufacturer (Qiagen, Valencia, Calif.), rPspA protein was purified by an affinity purification process with Ni 2ϩ -nitrilotriacetic acid-agarose support. The protein purity was verified by Coomassie blue staining of SDS-polyacrylamide gels, and the total amount of purified protein was determined by using the Pierce (Rockford, Ill.) protein assay kit with bovine serum albumin as a standard. Immunoblotting with the Xi126 PspA monoclonal antibody (32) was performed to confirm the purified protein.
Salmonella subcellular fractionation. The periplasmic fraction was prepared by a modification of the lysozyme-osmotic shock method (56) . Cultures grown in LB broth to an optical density at 600 nm (OD 600 ) of 0.8 were centrifuged at 7,000 ϫ g for 10 min, and the supernatant fluid was saved for analysis of secreted proteins. The cell pellets were resuspended in 800 l of 100 mM Tris-HCl buffer (pH 8.6) containing 500 mM sucrose and 0.5 mM EDTA. Hen egg white lysozyme (40 l of a 4-mg/ml stock solution) was added, followed immediately by the addition of 3.2 ml of 50 mM Tris-HCl buffer (pH 8.6) containing 250 mM sucrose, 0.25 mM EDTA, and 2.5 mM MgCl 2. After gentle agitation, the suspension was incubated for 15 min in an ice bath. Cells were removed by centrifugation at 7,000 ϫ g for 6 min followed by filtration of the supernatant through a 0.45 m-pore-size filter. The filtered supernatant fluid served as the periplasmic fraction. Cells resuspended in 4 ml of 20 mM Tris-HCl (pH 8.6) were disrupted by two passages through a French pressure cell (American Instrument Company, Silver Spring, Md.). Cell lysates were centrifuged at 7,000 ϫ g at 4°C for 6 min to remove unbroken cells. The supernatant fluid was then centrifuged at 132,000 ϫ g at 4°C for 1 h to separate the soluble fraction and insoluble cell envelopes. The soluble fraction contained the cytoplasmic proteins. To isolate the outer membrane fraction, total envelope pellets were suspended in 4 ml of 20 mM Tris-HCl (pH 8.6) containing 1% Sarkosyl and incubated for 30 min on ice. The outer membrane fraction was obtained as a pellet after centrifugation at 132,000 ϫ g at 4°C for 1 h. The pellet was resuspended in 4 ml of 20 mM Tris-HCl buffer (pH 8.6). The original culture supernatant was filtered (0.22 m-pore-size filter), and secreted proteins were precipitated with 10% trichloroacetic acid (1 h, 4°C). An equal volume of each fraction sample was separated by SDS-PAGE for Western blot analysis. By using the outer membrane protein preparation procedure described above, Salmonella outer membrane proteins (SOMPs) were prepared from S. enterica serovar Typhimurium 4746 cells grown in LB broth without galactose for analysis by enzyme-linked immunosorbent assay (ELISA). The use of SOMPs obtained from 4746 precludes LPS O-antigen contamination.
Construction of an S. enterica serovar Typhimurium vaccine strain. The ⌬crp mutation was introduced into S. enterica serovar Typhimurium 3339 by allelic exchange using the suicide vector pMEG-493 to yield 8499. The presence of the 680-bp deletion was confirmed by PCR with a primer set flanking crp (5Ј-AAA GTCGCAATGGAAGGC-3Ј and 5Ј-CGTAGACGACGATGGTCTTG-3Ј) and a strain phenotype of Mal Ϫ and nonmotility. The ⌬asdA16 mutation was then introduced into 8499 by P22HTint transduction from 8554 with the suicide vector pMEG-443 integrated into a strain with the ⌬asdA16 mutation, followed by sucrose selection to eliminate the suicide vector to yield 8501 (27) . The presence of the 1,242-bp asd deletion in 8501 was confirmed by PCR using flanking a asd primer set (5Ј-CGGAAATGATTCCCTTCCTAACG-3Ј and 5Ј-TATCTGCGTCGTCCTACCTTCAG-3Ј) (27) .
Immunization of mice. Two groups of five inbred 7-week-old female BALB/c mice were deprived of food and water for 4 h before infection. The recombinant S. enterica serovar Typhimurium 8501(pYA3494) vaccine (1.9 ϫ 10 9 CFU in 20 l of phosphate-buffered saline containing 0.01% gelatin [BSG]) grown in LB broth to an OD 600 of 0.8 was orally administered to BALB/c mice. The recombinant S. enterica serovar Typhimurium 8501(pYA3493) vaccine (2 ϫ 10 9 CFU in 20 l of BSG) was used as a vector control. Food and water were returned to the immunized mice 30 min after immunization. Blood was obtained by retroorbital puncture with heparinized capillary tubes at biweekly intervals. Following centrifugation at 4,000 ϫ g for 5 min, the serum was removed from the whole blood and stored at Ϫ20°C. Vaginal secretion specimens were collected in a 50-l BSG wash and stored at Ϫ20°C (59).
Pneumococcal challenge. To observe the immune response caused by pneumococcal infection after vaccination, a sublethal dose of 3.8 ϫ 10 5 S. pneumoniae WU2 CFU in 200 l of BSG was administered by intravenous (i.v.) injection to S. enterica serovar Typhimurium vaccine-immunized BALB/c mice at 16 weeks after primary immunization. The ability of the Salmonella-PspA vaccine to protect the immunized mice against S. pneumoniae was assessed by intraperitoneal challenge with 4.8 ϫ 10 3 CFU of S. pneumoniae in 100 l of BSG. The 50% lethal dose (LD 50 ) of S. pneumoniae WU2 in BALB/c mice was Ͼ10 6 CFU by i.v. administration (Larry McDaniel, personal communication) and Ͻ10 2 CFU by intraperitoneal administration (37). Significant differences in mortality were determined by chi-square analysis at day 21 after challenge. A difference was considered significant at a P value of Ͻ0.05.
ELISA. ELISA was used to assay antibodies in vaginal secretions and serum to S. enterica serovar Typhimurium LPS and SOMPs and to rPspA. Polystyrene 96-well flat-bottom microtiter plates (Dynatech Laboratories Inc., Chantilly, Va.) were coated with S. enterica serovar Typhimurium LPS (100 ng/well; Sigma), SOMPs (100 ng/well), or purified rPspA (100 ng/well). Antigens suspended in sodium carbonate-bicarbonate coating buffer (pH 9.6) were applied with 100-l volumes in each well. The coated plates were incubated at 37°C for 1 h, followed by an overnight incubation at 4°C. Free binding sites were blocked with a blocking buffer (phosphate-buffered saline [pH 7.4], 0.1% Tween 20, and 1% bovine serum albumin). Vaginal secretions and sera obtained from the same experimental group (five mice per group) were pooled and diluted 1:10 and 1:600, respectively. A 100-l volume of diluted sample was added to individual wells in duplicate and incubated for 2 h at 37°C. Plates were treated with biotinylated goat anti-mouse IgG, IgG1, or IgG2a (Southern Biotechnology Inc., Birmingham, Ala.) for sera and IgA for vaginal secretions. Wells were developed with streptavidin-alkaline phosphatase conjugate (Southern Biotechnology) followed by p-nitrophenylphosphate substrate (Sigma) in diethanolamine buffer (pH 9.8). Color development (absorbance) was recorded at 405 nm using an automated ELISA plate (model EL311SX; Biotek, Winooski, Vt. 
RESULTS

Construction of Asd
؉ vectors to use for antigen expression. Vaccine strains harboring mulicopy Asd ϩ vectors (pBR ori or pUC ori) containing the entire asd gene with its promoter synthesized the Asd protein at a much higher level than necessary to complement the chromosomal asd mutation in a balanced-lethal host-vector system. In fact, the 200-to 300-fold excess production of Asd in a strain such as 8554 (⌬asd16) with the pYA3334 Asd ϩ vector (pUC ori) increases the generation time slightly and the LD 50 10 -fold compared to the same strain with an Asd ϩ vector with the pSC101 ori or p15A ori. In an attempt to reduce the level of Asd, the asd promoter region was deleted to determine whether there would be sufficient transcription to permit a promoterless asd gene to complement the chromosomal ⌬asdA16 mutation. The asd gene sequence was amplified by PCR starting at bp 286 and ending at bp 1421 of the S. enterica serovar Typhimurium asd sequence (accession number AF015781) with an N-terminal BglII site and a C-terminal XbaI site. This sequence contains the Shine-Dalgarno (SD) sequence for ribosome recognition but lacks the Ϫ35 and Ϫ10 promoter sequence and ends just after the asd gene TAG stop codon. The BglII-XbaI DNA fragment was used to construct Asd ϩ vectors pYA3342 (pBR ori) and pYA3341 (pUC ori) ( Table 1) . It was possible to clone this fragment onto pSC101 ori or p15A ori vectors, but this did not result in sufficient Asd to permit construction of balancedlethal systems with strains such as 8554 which could grow in the absence of DAP. Both pYA3342 and pYA3341 complemented the asd mutations of E. coli 6212 and S. enterica serovar Typhimurium 4550. Salmonella strains possessing pYA3342 and pYA3341 produced significantly reduced amounts of Asd protein (39 kDa) compared to strains containing plasmids that had asd genes with the asd native promoter (Fig. 1 ). pYA3342 and pYA3341 in a ⌬asd S. enterica serovar Typhimurium strain such as 8554 yielded recombinants that had wild-type LD 50 s following oral inoculation of BALB/c mice. Plasmid pYA3342 ( Fig. 2A) was used for further construction.
Since export of PspA into the periplasmic space of Salmonella was inefficient and caused toxicity when the export depended on the signal sequence for PspA (37), we constructed a recombinant plasmid by cloning a DNA fragment specifying the signal sequence of ␤-lactamase which is efficiently transported into the periplasmic space in Salmonella. A 105-bp DNA fragment (nucleotides 4049 to 4153 of the sequence under accession number J01749) of the ␤-lactamase gene was PCR amplified from the pBR322 DNA template by using a pair of primers (N-terminal, 5ЈGCATTCATGAGTATTCAA CATTTCC3Ј-BspHI [underlined]; C-terminal, 5ЈCCGGAATT CTTCAGCATCTTTTACT3Ј-EcoRI [underlined]). The PCRamplified fragment included the N terminus of ␤-lactamase from the ATG start codon through the signal sequence (23 amino acids) plus 12 amino acids of the N terminus of the mature ␤-lactamase. These additional 12 amino acid residues were included to increase the efficiency of secretion of the recombinant protein (53) . The 105-bp PCR product was digested with BspHI and EcoRI enzymes and cloned into the NcoI site (compatible with the BspHI site) and EcoRI site of the Asd ϩ vector pYA3342, resulting in plasmid pYA3493 (Fig.  2B) . The in-frame position of the ␤-lactamase signal sequence was confirmed by nucleotide sequencing. Transcription promoted by P trc can be stopped by the 5ST1T2 transcriptional terminator located following the multicloning sites. pYA3493 was stably maintained for 50 or more generations in E. coli 6212 and S. enterica serovar Typhimurium (⌬asd) hosts grown in the presence or absence of DAP.
Construction of the rPspA-expressing plasmid. A highly immunogenic ␣-helical region of PspA from amino acid residue 3 to 257 (765 bp; 255 amino acids) of the mature PspA Rx1 protein (588 amino acids) was selected to use as a test antigen in antigen delivery by a Salmonella carrier. The 765-bp DNA fragment of the pspA gene of S. pneumoniae Rx1 was PCR amplified from the pYA3193 DNA template with a pair of primers (N-terminal, 5ЈCCGGAATTCTCTCCCGTAGCCA GTCAGTCT3Ј; C-terminal, same as used in the construction of His 6 -tagged PspA, which introduces the TAA TAG stop codons after the pspA coding sequences). The PCR product, digested with EcoRI and HindIII enzymes, was cloned into the EcoRI and HindIII sites of pYA3493, resulting in pYA3494 (Fig. 3) . The in-frame fusion of the rPspA with the ␤-lactamase signal sequence was confirmed by nucleotide sequencing. E. coli 6212 harboring pYA3494 expressed rPspA as approximately 1% of the total cell protein (data not shown).
Expression and subcellular localization of rPspA in Salmonella. An S. enterica serovar Typhimurium strain was constructed to examine expression and subcellular localization of rPspA. ␤-Galactosidase production from the atrB13::MudJ allele in 8599 was used as a cytoplasmic protein marker and as an indicator of membrane leaking in the examination of subcellular fractionations. No periplasmic protein marker was used, since the use of the ␤-lactamase signal sequence in the pYA3494 construct precluded use of ␤-lactamase and the commercially available monoclonal antibody to the E. coli maltose binding protein (Sigma) did not react with this protein from S. enterica serovar Typhimurium. To observe rPspA expression, plasmid pYA3494 was introduced into S. enterica serovar Typhimurium 8599. 8599 harboring pYA3493 (vector alone) was used as the control (data not shown).
With the expectation of the periplasmic secretion of the rPspA, various subcellular fractions, including cytoplasm, periplasm, outer membrane, and culture supernatant of 8599(pYA3494), were prepared to examine the location of rPspA. Although the calculated size of rPspA was approximately 30 kDa, PspA-specific monoclonal antibody Xi126 reacted with an approximately 35-kDa protein (Fig. 4) . Aberrant migration of a PspA protein has been seen in previous studies (37, 54) . Although a large amount of the rPspA resided in the cytoplasmic fraction, half of the rPspA was detected in the periplasmic fraction and the culture supernatant fluid. Little or no rPspA was detected in the outer membrane fraction. Densitometry analyses of immunoreactive bands showed that approximately 50% of the rPspA was located in the combined periplasm (25%) and culture supernatants (25%). In the immunoblot analyses of subcellular fractions with anti-␤-galactosidase and -OmpC monoclonal antibodies, the ␤-galactosidase and OmpC proteins were detected in the cytoplasm and outer membrane fractions, respectively, suggesting that the rPspA detected in the periplasmic fraction and culture supernatant fluid was actively secreted instead of resulting from nonspecific membrane leaking or cell death by lysis.
Recombinant S. enterica serovar Typhimurium ⌬crp-28 vaccine expressing rPspA antigen. pYA3493 (vector control) and pYA3494 (encoding rPspA) were electroporated into the ⌬crp-28 ⌬asdA16 strain 8501. The S. enterica serovar Typhimurium 8501 (⌬crp-28 ⌬asdA16) vaccine strain containing pYA3494 expressed the rPspA protein at an approximate molecular mass of 35 kDa. In the analyses of Coomassie bluestained SDS-polyacrylamide gels, the amount of rPspA protein was as much as approximately 1 to 2% of the total 8501(pYA3494) proteins (Fig. 5) . With results consistent with those seen in the rPspA localization analysis (75% of rPspA cell associated [50% in cytoplasm and 25% in periplasm] and 25% of rPspA secreted), the rPspA expressed in the 8501 vaccine strain was secreted into the culture supernatant along with other secreted proteins. To examine the stability of plasmids pYA3493 and pYA3494 in Salmonella 8501 in vitro, 8501 cells containing pYA3493 and pYA3494 were cultured with daily passage of 1:1,000 dilutions for five consecutive days in L broth containing DAP. All 8501 clones examined (300 clones/day) kept the Asd ϩ plasmid pYA3493 and pYA3494, indicating that pYA3493 and pYA3494 were very stable in the 8501 vaccine strain. Cells obtained from the last-day culture of the stability test expressed amounts of the 35-kDa rPspA similar to those from the first day (data not shown), suggesting stable expression of rPspA without rearrangements.
Immune responses in mice after oral immunization with the recombinant S. enterica serovar Typhimurium vaccines. All mice orally administered a single dose of 1.3 ϫ 10 9 CFU S. enterica serovar Typhimurium 8501(pYA3493) (vector control) survived for the 30-day monitoring period. Those mice were protected for a 30-day observation period against wildtype 3339 (LD 50 , Ͻ10
6 CFU) challenge (1.7 ϫ 10 9 CFU) 30 days after the initial immunization. There were no survivors in a group of unimmunized mice challenged with 1.7 ϫ 10 7 CFU of 3339. These results indicate that 8501 with an Asd ϩ vector is avirulent for mice and elicits a protective immune response against challenge with S. enterica serovar Typhimurium.
A single dose of S. enterica serovar Typhimurium 8501(pYA3494) (1.9 ϫ 10 9 CFU) or 8501(pYA3493) (control, 2 ϫ 10 9 CFU) was orally administered to 7-week-old female BALB/c mice. All immunized mice survived, and we did not observe any signs of disease in the immunized mice during the entire experimental period. The antibody responses to Salmonella LPS and SOMPs and to the foreign antigen rPspA in the sera and the vaginal secretions of the immunized mice were measured. The serum IgG responses to LPS, SOMPs, and rPspA are presented in Fig. 6 . At 2 weeks after administration, little IgG response to the antigens was observed. Maximal anti-LPS, -SOMP, and -rPspA IgG levels without boost immunization were detected at 6 weeks postimmunization.
At 17 weeks postimmunization, we infected mice i.v. with a sublethal dose (3.8 ϫ 10 5 CFU) of the virulent S. pneumoniae WU2 strain to monitor the changes of anti-rPspA antibody titers. Sublethal i.v. infection with S. pneumoniae did not kill mice immunized with the 8501(pYA3493) or 8501 (pYA3494) vaccine. Because native PspA is a highly immunogenic pneumococcal surface protein, the pneumococcal challenge boosted rPspA-specific immune responses in 8501 (pYA3494)-immunized mice (Fig. 6) . In comparison to the anti-rPspA IgG level (A 405 , 0.81) at 12 weeks after S. enterica serovar Typhimurium 8501(pYA3494) immunization, the pneumococcal challenge boosted 53% more anti-rPspA IgG (A 405 , 1.24) 1 week later. This suggests that the S. enterica serovar Typhimurium 8501-rPspA vaccine induces immunological memory for a rapid responsiveness to subsequently administered PspA antigen. Anti-rPspA IgG was not detected in sera obtained from mice immunized with 8501(pYA3493), the vector control vaccine. The 8501(pYA3493) vaccine elicited anti-LPS and -SOMP IgG responses with kinetics and levels similar to those induced by 8501(pYA3494). These results suggest that Salmonella-delivered rPspA antigen had minimal influence on the immune response to Salmonella itself.
IgA levels, mostly secretory IgA, for LPS, SOMPs, and rPspA in the vaginal fluids of immunized mice were measured. The 8501(pYA3493) and 8501(pYA3494) vaccines elicited anti-LPS and anti-SOMP IgA. rPspA-specific IgA was detected in the vaginal fluids from mice immunized with 8501 (pYA3494) but not in those from mice immunized with the 8501(pYA3493) vector-only control (Fig. 7) .
IgG isotype analyses. The types of immune responses to Salmonella LPS and SOMPs and to the rPspA were further examined by measuring the levels of IgG isotype subclasses IgG2a and IgG1. The Th1-helper cells direct cell-mediated immunity and promote class switching to IgG2a, and Th2 cells provide potent help for B-cell antibody production and promote class switching to IgG1 (39, 51) . IgG2a isotype dominant responses were observed for the Salmonella LPS and SOMP antigens (Fig. 8) . The IgG2a/IgG1 ratios for anti-LPS and -SOMPs in sera obtained from mice immunized with 8501(pYA3493) were not significantly different from those from mice immunized with 8501(pYA3494) (LPS, P ϭ 0.07; SOMPs, P ϭ 0.054). The IgG2a/IgG1 ratios for anti-SOMPs (ranging from 6.4 to 11.5) are higher than those for LPS (ranging from 1.1 to 2.5), with statistical significance [8501(pYA3493), P ϭ 0.0004; 8501(pYA3494), P ϭ 0.0003]. Th1-type dominant immune responses are frequently observed after immunization with attenuated Salmonella (30, 40) . In contrast to the type of immune responses to LPS and SOMPs, a Th1-and Th2-type mixed response was observed for the rPspA antigen. Although the IgG2a levels were higher than IgG1 levels in the early Evaluation of protective immunity. To examine the ability of Salmonella-rPspA vaccines to protect against pneumococcal infection, BALB/c mice were immunized with either S. enterica serovar Typhimurium 8501(pYA3493) (dose of 1.3 ϫ 10 9 CFU) or 8501(pYA3494) (dose of 1.7 ϫ 10 9 CFU). At 10 weeks after the initial immunization, a second dose of 10 9 CFU of each vaccine was administered. We did not detect weakness or disease signs in vaccinated mice during the immunization periods. At 5 weeks after the second immunization, mice were challenged intraperitoneally with 4.8 ϫ 10 3 CFU (50 times the LD 50 ) of S. pneumoniae WU2. Sixty percent of the mice immunized with 8501(pYA3494) were protected from pneumococcal challenge, with statistical significance (P Ͻ 0.05). This challenge dose killed 100% of unimmunized and 8501 (pYA3493)-immunized mice (Table 2) . Following challenge, mice unimmunized or immunized with 8501(pYA3493) died much faster, with death at a mean of day 2, than mice immunized with 8501(pYA3494), which died at a mean of day 5.
DISCUSSION
Attenuated Salmonella strains constructed by recombinant DNA technology have been developed as live vaccines for humans and animals to prevent disease caused by Salmonella infections. The ability of live recombinant Salmonella vaccines to colonize the gut-associated lymphoid tissue (Peyer's patches) and visceral lymphoid tissues following oral administration is beneficial in that it stimulates all arms of the immune response, including mucosal, humoral, and cellular immunities (13, 17, 34) . Recombinant Salmonella vaccines have also been developed as multivalent vaccines to deliver recombinant antigens originating from viruses, bacteria and parasites (13, 34) .
Analysis of convalescent-phase sera from patients or animals infected with bacterial pathogens reveals that the proteins located in the envelopes of or secreted by the bacterial pathogens act as dominant immunogens for the immune responses (31, 38, 58) . These observations indicate that envelope and secreted proteins are highly immunogenic and/or more readily interact with antigen-presenting cells due to their subcellular location. Translocation of such highly immunogenic antigens into the cell envelope or secretion from the cell should increase the strength of the immune response elicited by vaccine strains expressing foreign antigens. In the development of attenuated Salmonella-based multivalent vaccines, a preferable system would have a recombinant antigen secreted from the cytoplasm of Salmonella vaccines (19, 20) . ␤-Lactamase, encoded by the ampicillin resistance gene, is a well-characterized periplasmic secreted protein in gram-negative bacteria (43) . The ␤-lactamase gene contained in plasmid pBR322 was originally obtained from an S. enterica serovar Paratyphi B isolate (3, 14) . It is well known that ␤-lactamase produced from pBR322 is secreted to the periplasmic space of gram-negative bacteria, and its translocation depends upon the presence of a signal sequence consisting of 23 amino acid residues at the N terminus (26, 43) . Evidence obtained from previous studies confirms that the signal sequence plus an additional 12 amino acids of the mature ␤-lactamase are required to translocate ␤-lactamase through the cytoplasmic membrane of gram-negative bacteria (28, 53) . Fusion of a protein to the ␤-lactamase signal peptide promotes the secretion of the fusion protein into the periplasm of E. coli (42, 53) . We reasoned that a protein antigen attached to the ␤-lactamase signal peptide should be secreted into the periplasm of Salmonella vaccine strains. The pYA3493 plasmid (Fig. 2B ) constructed in this study was designed to use for the periplasmic secretion of recombinant antigens for antigen delivery by Salmonella vaccines.
The recombinant plasmid pYA3494 (pBR ori) (Fig. 3) was constructed for the periplasmic secretion of the ␣-helical region of the PspA Rx1 . In contrast to the previously described PspA-specifying pYA3193 (37), pYA3494 was maintained stably (100%) over 50 generations in the S. enterica serovar Typhimurium vaccine strain grown in the presence of DAP. Both E. coli and Salmonella containing pYA3494 expressed the rPspA protein with an apparent molecular mass of 35 kDa, and the rPspA proteins were detected in the periplasm (25%) as well as in the culture supernatant (25%) (Fig. 4) . The Nterminal His 6 -tagged rPspA protein (no apparent signal peptide) expressed in S. enterica serovar Typhimurium 8599 containing pYA3496 was detected only in the cytoplasm and not in the periplasm of the Salmonella host (data not shown). These results suggest that the signal peptide and 12 residues of the N terminus of ␤-lactamase (present in pYA3494) promote the periplasmic secretion of rPspA. The mechanism to explain how rPspA was translocated from the periplasm outside cells (Fig.  4 and 5 ) remains unknown. The secondary and tertiary structures of rPspA may permit it to traverse through the Salmonella outer membrane. Alternatively, accumulated rPspA in the periplasm may be encapsulated in membrane vesicles which are discharged from the cells. Membrane vesicles have been identified in many gram-negative bacteria (2), and Ciofu et al. (10) reported that ␤-lactamase was packaged into membrane vesicles and secreted from Pseudomonas aeruginosa. Approximately 50% of the rPspA remained in the cytoplasm, perhaps because the amount of endogenous signal peptidase necessary to process all of the overexpressed rPspA is limiting. Alternatively, it has been reported that the C-terminal sequence of mature ␤-lactamase is important for the efficient periplasmic secretion of ␤-lactamase, along with the signal sequence (28) .
The immunogenicity and appropriate subcellular location of rPspA in the Salmonella vaccine strain may contribute to the (Fig. 7) . It is likely that mucosal immunity will act as a primary immune defense system against natural infection by S. pneumoniae. Detection of anti-rPspA IgG with a typical antibody response in sera from Salmonella-rPspA vaccine-immunized mice (Fig. 6) indicates that the 8501(pYA3494) vaccine likely reached appropriate lymphoid tissues to stimulate a systemic immune response. Similar levels of anti-LPS and -SOMP IgG were induced by strains 8501(pYA3493) (vector) and 8501(pYA3494), suggesting that rPspA-specific immunity did not interfere with immunity against Salmonella itself. In T-cell-dependent, antigen-specific immune responses, Th1 cells direct cell-mediated immunity and promote class switching to IgG2a. Th2 cells direct humoral immunity and promote class switching to IgG1 and IgA (39, 51) . To date, the mechanism determining Th1-or Th2-type immunity to a given antigen is not well understood. Th2-type immune responses are rare in the immune response elicited by attenuated Salmonella vaccines (11, 41) . While Th1-type dominant responses were observed for the LPS and SOMPs in this study, mixed Th1-and Th2-type immune responses were observed for rPspA (Fig. 8) . After 10 weeks postimmunization, the Th2-type response became dominant. The mechanisms stimulating these types of immune responses by the Salmonella-rPspA vaccine remain unknown. It has been reported that oral immunization of purified PspA with the mucosal adjuvant cholera toxin in mice elicited Th2-type immune responses (57) . In the development of pneumococcal vaccines, the anti-rPspA IgG isotype switching to a mixed or IgG1-dominant type along with a mucosal IgA response, indicating induction of a strong Th2-type humoral immune response, is preferred to prevent colonization of S. pneumoniae in the respiratory tract (pneumonia) or ear mucosa (otitis media) (33, 55) . A sublethal challenge of S. pneumoniae boosted the rPspA immune responses with maintenance of the IgG1 isotype dominant response observed before infection.
Mice orally vaccinated with Salmonella-rPspA vaccine were significantly protected (60%) (P Ͻ 0.05) against virulent S. pneumoniae WU2 intraperitoneal challenge at 10 weeks postimmunization. These results indicate that the Salmonella 8501 vaccine, which expresses the rPspA by an improved antigen expression system, induces protective immunity against pneumococcal infection, and they are consistent with the results demonstrating that the ␣-helical portion of PspA represents a protective domain (7) .
In conclusion, the results of this study demonstrate that a recombinant attenuated Salmonella vaccine expressing rPspA antigen elicited mixed Th1-and Th2-type immune responses to rPspA and protected mice against pneumococcal challenge. Recombinant attenuated Salmonella-rPspA vaccines may have great potential for use for inducing effective protection against pneumococci which establish infection via a mucosal surface.
However, there are some issues that need to be evaluated in future studies. The factors causing augmented Th2-type immune responses will be investigated. It remains to be examined whether rPspA secretion could be associated with the formation of membrane vesicles. Further modifications of the rPspA antigen expression construct may be required to enhance the rPspA secretion and to induce antibodies which can opsonize diverse pneumococcal strains with high avidity. Answers to these questions will subsequently improve the recombinant attenuated Salmonella-based pneumococcal vaccine.
